tradingkey.logo

AbbVie falls as weak aesthetics segment sales overshadow Q3 results beat

ReutersOct 31, 2025 1:41 PM

Shares of drugmaker AbbVie ABBV.N fall 3.5% at $220 in early trading

ABBV's sales from its aesthetics products portfolio, which includes anti-wrinkle treatment Botox, fell 3.7% from last year

"Another weaker quarter for the Aesthetics business could raise some eyebrows... continued headwinds mount across products, including Botox and fillers," says BMO Capital Markets analyst Evan Seigerman

Co reports Q3 adj. profit of $1.86/shr vs analysts' average estimate of $1.77/shr - LSEG data

Co's quarterly revenue of $15.78 billion beats analysts' average expectation of $15.59 billion

ABBV raises annual profit forecast to $10.61-$10.65/shr from its previous forecast of $10.38-$10.58/shr

Including sessions move, stock up ~28% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI